Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Amgen’s Xgeva Wins U.K. NICE Backing for Some Cancer Patients

Amgen Inc.’s Xgeva won the backing of the U.K.’s health-cost agency as a treatment for some patients whose cancer has spread to their bones.

The drug, also called denosumab, is an option for breast-cancer patients with bone metastases, though not for men with prostate cancer that has spread, the National Institute for Health and Clinical Excellence said today in a statement on its draft recommendations. Xgeva may also be a cost-effective treatment for patients with solid tumors other than breast or prostate cancers if zoledronic acid or disodium pamidronate would otherwise be prescribed for these patients, according to the agency, known as NICE.

The drug should only be prescribed if Amgen, based in Thousand Oaks, California, provides it at a discounted rate, NICE said, adding that the discount was confidential.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.